The clonal expansion of mature B lymphocytes is a common feature of small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL), two common neoplastic diseases. With a lifetime risk of about 0.57%, CLL is the most prevalent form of adult leukemia in the Western world. The condition usually manifests in men and is diagnosed in those between the ages of 70 and 72. The treatment landscape for sickle cell disease (CLL/SLL) has changed over time, bringing with it a variety of therapeutic alternatives such as immunotherapy, targeted medicines such BTK inhibitors, chemotherapy, and novel drug delivery techniques. A promising method for drug delivery that increases the solubility and bioavailability of anti-cancer drugs is the use of polymeric micelles. Due to the enhanced permeability and retention (EPR) effect in tumor tissues, which is caused by leaky blood vessels and impaired lymphatic drainage, these nanoscale structures—which are created by the self-assembly of amphiphilic block copolymers—allow targeted drug delivery. This paper discusses the fundamental concepts of polymeric micelles, their mechanisms of action, and their potential applications in improving therapeutic outcomes for CLL/SLL patients.

Dr. Rajan Kalamkar* & Dighe Anjali, Tiwari Nikita, Patil Dilisha

Polymeric Micelles, Targeted Drug Delivery, Nanomedicine